Rating Change
Piper Sandler reiterated its Overweight rating on Bristol-Myers Squibb Company (NYSE:BMY) on October 26, 2026.
reiterateNYSE:BMY
Piper Sandler Reiterates Overweight Rating on Bristol-Myers Squibb Company (BMY)
Piper Sandler reiterated its Overweight rating on Bristol-Myers Squibb Company (NYSE:BMY) on October 26, 2026.
At publication ·
What changed
Bristol-Myers Squibb Company (NYSE:BMY) · reiterate
- Firm
- Piper Sandler
- Rating
- Overweight to Overweight
- Price at event
- $61.61
- Market capitalization
- $104.2B
At a glance
Key takeaways
- Piper Sandler reiterated an Overweight rating on Bristol-Myers Squibb on October 26, 2026, with the stock trading at $61.61.
Market Context
Bristol-Myers Squibb Company operates in the Healthcare sector. The stock currently trades at $61.61 with a market capitalization of $104.2B. The stock has gained 15.0% over the past 52 weeks.
Analyst coverage from Piper Sandler provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Bristol-Myers Squibb Company.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Bristol-Myers Squibb Company
Among the 10 most recent ratings: 3 Buy, 6 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 26, 2026 | Piper Sandler | Overweight | N/A |
| Oct 13, 2026 | Wells Fargo | Equal-Weight | N/A |
| Oct 08, 2026 | Cantor Fitzgerald | Neutral | N/A |
| Oct 07, 2026 | Morgan Stanley | Underweight | N/A |
| Oct 05, 2026 | Leerink Partners | Market Perform | N/A |
Related Tools: Analyst Ratings Dashboard | View BMY Stock Page
Frequently Asked Questions
What does the Overweight rating mean for BMY?
A rating of Overweight from Piper Sandler reflects the analyst's outlook on Bristol-Myers Squibb Company (NYSE:BMY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BMY forecast page.
